SELLAS Stock More Than Doubles After Phase 3 Trial Win
Why is SELLAS stock up today?
SELLAS Life Sciences (SLS) stock more than doubled on Tuesday, from a $7.47 close to above $17, after its Phase 3 leukemia vaccine trial met its survival goal, cutting death risk by 41%.
Key numbers
| Reduction in risk of death | 41%Hazard ratio 0.59 vs best available treatment |
|---|---|
| Median survival, GPS | 24.0 monthsvs 14.7 months on standard care |
| Statistical significance (p-value) | 0.035Usual cutoff is 0.05 |
| SLS share price | $17.83+139% vs $7.47 prior close at 9:50 a.m. ET |
| Market value (per MarketBeat) | $3.68BIntraday; shares traded as high as $27.05 |
What happened
SELLAS Life Sciences (SLS) stock more than doubled on Tuesday, from a $7.47 close to above $17, after its Phase 3 leukemia vaccine trial met its survival goal, cutting death risk by 41%. The trial tested a cancer vaccine, galinpepimut-S (GPS), in 126 people with a blood cancer (AML) who were in remission but could not have a stem cell transplant. People on the vaccine lived a median of 24 months, versus 14.7 months on standard care. SELLAS aims to file for FDA approval in the first half of 2027.
Why it matters
SELLAS Life Sciences is a small drug developer, and a successful Phase 3 trial is the step that decides whether it can ask regulators to approve a medicine. Few treatments exist for AML patients who cannot have a transplant, so living about nine months longer on average would be meaningful if it holds up. The figures are early results from the company and have not been peer reviewed, and the test result (p=0.035) cleared the usual 0.05 bar by a modest margin.
Who this affects
- MarketmixedMedium impact
- Biotech traders saw wild swings, with temporary trading halts.
- CompanybullishHigh impact
- SELLAS shareholders gain sharply; an FDA filing is targeted for 2027.
- CompetitorsmixedLow impact
- Other AML drug makers could face a new maintenance option.
- IndustrybullishMedium impact
- Cancer vaccines get fresh evidence of a survival benefit.
SELLAS Life Sciences vs Syndax, Kura Oncology
How we got here
Maxim Group analyst keeps Buy rating and $30 price target ahead of trial data.
SELLAS reports REGAL trial met its survival goal; shares surge in premarket trading.
Trading is temporarily halted several times as the stock swings sharply.
What to watch
- FDA meeting on a faster filing path, then a drug application for GPSH1 2027
- Full secondary results at a medical conference and in a peer-reviewed journalNot yet scheduled
- Early data from SELLAS's second AML drug, tambiciclib (SLS009)Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →

Mayne Pharma Stock Jumps 86% After Richter Takeover Deal
Mayne Pharma (MYX) backed a cash offer of A$6.40 a share, a 99.4% premium, from Hungary's Gedeon Richter.

Oil Falls to $92 as Glut Fears Outweigh Hormuz Attacks
Brent crude (BZ=F) slipped 0.5% Tuesday while Vice President Vance said Iran war won't last two more years.

Trump-Kim Meeting Odds Jump to 18% After APEC Summit Hint
Traders on Polymarket added 13 points in a day after Trump said he may meet Kim at China's APEC summit.